Biohaven Ltd.
$10.82
▲
1.87%
2026-04-21 05:39:01
www.biohaven.com
NYQ: BHVN
Explore Biohaven Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.65 B
Current Price
$10.82
52W High / Low
$24.06 / $7.48
Stock P/E
—
Book Value
$0.39
Dividend Yield
—
ROCE
-222.16%
ROE
-3.11%
Face Value
—
EPS
$-6.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
274
Beta
3.62
Debt / Equity
546.58
Current Ratio
3.18
Quick Ratio
3.18
Forward P/E
-4.7
Price / Sales
—
Enterprise Value
$1.34 B
EV / EBITDA
-1.93
EV / Revenue
—
Rating
Buy
Target Price
$22.44
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 2. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 3. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
| 4. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 5. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 6. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 7. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -142.73 M | -169.38 M | -211.7 M | -221.56 M | -189.93 M | — |
| Net Profit | -145.56 M | -173.44 M | -198.15 M | -221.68 M | -186.84 M | — |
| EPS in Rs | -0.97 | -1.15 | -1.32 | -1.47 | -1.24 | -1.7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -745.38 M | -885.11 M | -436.05 M | -567.93 M |
| Net Profit | -738.82 M | -846.42 M | -408.17 M | -570.28 M |
| EPS in Rs | -4.91 | -5.63 | -2.71 | -3.79 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 451.45 M | 615.11 M | 513.21 M | 661.78 M |
| Total Liabilities | 399.38 M | 191.67 M | 85.24 M | 123.01 M |
| Equity | 52.07 M | 423.44 M | 427.98 M | 538.77 M |
| Current Assets | 368.33 M | 538.47 M | 442.45 M | 586.97 M |
| Current Liabilities | 115.93 M | 154.23 M | 55.42 M | 90.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -609.44 M | -582.45 M | -331.73 M | -297.69 M |
| Investing CF | 300.56 M | -244.97 M | 129.83 M | -304.79 M |
| Financing CF | 439.12 M | 677.77 M | 211.91 M | 767.6 M |
| Free CF | -610.15 M | -586.5 M | -334.77 M | -338.76 M |
| Capex | -0.71 M | -4.05 M | -3.05 M | -41.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -107.37% | 28.43% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.